Advertisement

Malignant Lymphomas Introduction

  • Theodoros P. Vassilakopoulos
  • George J. Pissakas
Chapter

Abstract

Lymphoproliferative neoplasms are mainly divided into 2 major categories: Hodgkin lymphoma (HL) with an annual incidence of ~2,5-3/100000 and non-Hodgkin lymphomas (NHL), which are approximately 7 to 8-fold more common. NHL constitute a heterogenous group of disorders: 85% are of B-cell and 15% of T-cell origin. Malignant lymphomas are currently classified according to the 2016 WHO classification scheme. Among NHL, diffuse large B-cell lymphomas (DLBCL) are the most common subtype (31% of the total), followed by follicular lymphomas (~25%), extranodal marginal (MALT) lymphomas (8%), mantle cell lymphoma (6%) and primary mediastinal large B-cell lymphoma (PMLBCL) (2-3%). Altogether, the common “nodal” T-cell lymphomas (peripheral T-cell NOS, angioimmunoblastic and anaplastic large cell lymphoma) comprise ~8% of the total cases of NHL. It should be noted that small lymphocytic lymphoma and B-chronic lymphocytic leukemia (B-CLL) are reported to account for ~10% of NHL cases. However, B-CLL is a separate entity with an annual incidence of 4,5-5,5/100000. In everyday practice, “clinical staging” according to the Ann Arbor or Lugano system is based on clinical examination, chest X-rays, whole-body CTs (except of brain) and bone marrow biopsy. MRI, US, brain imaging, bone scanning, GI endoscopy etc, are performed in the appropriate clinical setting. Recently, 18-fluoro-deoxy-glucose (18-FDG) positron emission tomography combined with CT (PET/CT) has been strongly recommended for staging and evaluation of response to therapy in various lymphoma subtypes, mainly HL and aggressive B-cell lymphomas, but also in all 18-FDG avid lymphoma subtypes sparing the need for most of the specific studies.

References

  1. 1.
    Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al (eds) (2008) WHO classification of tumors of haematopoietic and lymphoid tissues, 4th edn. International Agency for Research on Cancer, LyonGoogle Scholar
  2. 2.
    Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R et al (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127:2375–2390CrossRefGoogle Scholar
  3. 3.
    Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M (1971) Report of the committee on Hodgkin’s disease staging classification. Cancer Res 31:1860–1861PubMedGoogle Scholar
  4. 4.
    Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC et al (1989) Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds meeting. J Clin Oncol 7:1630–1636CrossRefGoogle Scholar
  5. 5.
    Barrington SF, Mikhaeel GN, Kostakoglu L, Meignan M, Hutchings M, Müeller SP et al (2014) Role of imaging in the staging and response assessment of lymphoma: consensus of the international conference on malignant lymphomas imaging working group. J Clin Oncol 32:3048–3058CrossRefGoogle Scholar
  6. 6.
    Juweid ME, Stroobants S, Hoekstra OS et al (2007) Use of positron emission tomography for response assessment of lymphoma: consensus of the imaging Subcommittee of International Harmonization Project in lymphoma. J Clin Oncol 25:571–578CrossRefGoogle Scholar
  7. 7.
    Cheson BD, Pfistner B, Juweid ME et al (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25:579–586CrossRefGoogle Scholar
  8. 8.
    Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Lister TA et al (2014) Recommendations for the initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32:3059–3067CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Theodoros P. Vassilakopoulos
    • 1
  • George J. Pissakas
    • 2
  1. 1.Department of Haematology, Laikon General HospitalNationaland Kapodistrian University of AthensAthensGreece
  2. 2.Head of Radiation Oncology DepartmentAlexandra General HospitalAthensGreece

Personalised recommendations